CE15 - Immunologie, Infectiologie et Inflammation 2020

Hormonal regulation of ILC – HormonoILC

Understanding sex bias in allergic asthma: how do androgens regulate ILC2?

Sex bias exists in immunity. Women develop stronger immune responses than men, making them more resistant to infections, but more likely to develop autoimmune and allergic diseases. This is the case for allergic asthma, which in adults, is more common in women. Our project aims to identify the cellular and molecular mechanisms underlying these differences.

Understanding how androgens regulate ILC2

ILC2 are major players in the initiation of allergic asthma. We have shown for the first time in previous studies that there is a sex bias in this population. Tissues from females have increased numbers of ILC2 in both homeostatic and inflammatory conditions. We assessed the role of sex hormones in these differences. While we excludde a role for estrogens, we found that androgens are negative regulators of ILC2 biology. Intrinsic activation of the androgen receptor (AR) in ILC2 is responsible for the sex-related differences observed during inflammation. In the absence of AR activation in ILC2, males now have comparable numbers of ILC2 to females, which is associated with asthma exacerbation. The aim of our project is now to understand what mechanisms are involved in the regulation of ILC2 by androgens. We will investigate at which stages of ILC2 development androgens act. We hypothesised, supported by our preliminary data, that androgens may act as a negative regulator of ILC2 by two non-exclusive mechanisms, both during their development in the bone marrow and once they reside in the tissue.

To assess the influence of AR-dependent signaling on ILC2, we will generate a genetic model that allows conditional deletion of the RA in lymphoid populations. This model will allow us to assess whether RA modifies the development of ILC2 as well as their number and location in tissues under homeostatic conditions and in models of allergic asthma. In parallel to unbiased exploratory methods, we wish to test, among other candidates, the role of KLRG1 in the inhibitory effect of androgens on ILC2. Indeed, we could show that the expression of KLRG1, a putative checkpoint inhibitor of ILC2, is increased by AR signalling in ILC2.

We have generated AR-deficient mouse model in the lymphoid compartment and have started its characterisation. In the absence of AR in ILC2, sex bias is no longer observed, either in homeostatic or inflammatory conditions. With this model now in our hands, we will now be able to assess the impact of AR deletion on the development of ILC2 and on their maintenance/localisation in the periphery. Regarding the role of KLRG1, we were able to exclude that KLRG1 is required for the inhibitory effect of androgens in acute asthma models. KLRG1 deficiency does not alter the number or the ability to produce cytokines in either male or female mice (Blanquart et al., 2022).

This work should allow help us identify not only the mechanisms behind sex bias in immunity, but also, more globally, to identify mechanisms behind the regulation of ILC2. As a result of this project, we plan to evaluate whether, as in mice, androgens regulate ILC2 in humans.

Targeting androgen signaling in ILC2s protects from IL-33-driven lung inflammation, independently of KLRG1.
Blanquart E, Mandonnet A, Mars M, Cenac C, Anesi N, Mercier P, Audouard C, Roga S, Serrano de Almeida G, Bevan CL, Girard JP, Pelletier L, Laffont S*, Guéry JC*. J Allergy Clin Immunol. 2022 Jan.
* co-last, co-corresponding.
www.jacionline.org/article/S0091-6749(21)00725-9/fulltext

While sex differences in susceptibility to infections, allergy or autoimmune diseases are well documented, the underlying biological mechanisms are not sufficiently studied. At the onset of adolescence, asthma becomes less prevalent in men than in women, suggesting a protective role of male sex hormones. Based on the crucial role of group 2 innate lymphoid cells (ILC2) in the induction of airway inflammation, we made the hypothesis that ILC2 could be influenced by sex hormones. We could demonstrate for the first time that androgen, via the activation of its receptor AR (androgen receptor) acts as a powerful negative regulator of ILC2 development and expansion. In this proposal, we will determine the molecular mechanisms behind these observations. Our project will help to characterize new molecular mechanisms regulating ILC2 and will lead to a better understanding of the mechanisms responsible for sex-differences in immune responses.

Project coordination

Sophie LAFFONT-PRADINES (Inserm Occitanie Pyrénées)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partnership

Inserm - CPTP Inserm Occitanie Pyrénées

Help of the ANR 362,577 euros
Beginning and duration of the scientific project: February 2021 - 42 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter